Newsroom
Truveta news releases
New study reveals major gaps in follow-up care for patients with heart failure
Most patients with newly identified heart failure did not receive repeat heart function assessment, despite guideline recommendations BELLEVUE, Wash.—May 21, 2026—A new peer-reviewed study led by Truveta and collaborators at Yale School of Medicine, Yale New Haven...
Truveta and Knit Health announce collaboration to power a new generation of clinical AI
Combining one of the nation’s most comprehensive real-world clinical datasets with next-generation behavioral AI models to transform care delivery and patient outcomes BELLEVUE, Wash. and SAN FRANCISCO, Calif.—May 12, 2026—Truveta and Knit Health today announced a...
Truveta unveils Truveta Intelligence, delivering real-time insights from real-world data
New AI-powered experience removes the time-to-evidence barrier, enabling healthcare leaders to better understand and make informed decisions based on what’s happening in care today BELLEVUE, Wash.—April 28, 2026— Truveta today announced Truveta Intelligence, a new...
Truveta deepens health system leadership with appointment of Erik Wexler to Board of Directors
Providence President and CEO brings extensive experience advancing innovation, operations, and patient-centered care at scale. BELLEVUE, Wash.— March 31, 2026—Grounded in its mission of Saving Lives with Data, Truveta today announced the appointment of Erik Wexler,...
Truveta deepens financial leadership with appointment of Henry Ford Health executive Robin Damschroder, FACHE as Board Chair
Veteran healthcare finance executive brings decades of experience advancing disciplined value creation. BELLEVUE, Wash.— March 31, 2026—Grounded in its mission of Saving Lives with Data, Truveta today announced that Robin Damschroder, FACHE, Executive Vice President,...
FDA cardiovascular indication for semaglutide led to short-term uptake but persistent treatment gaps among high-risk patients, new Truveta study finds
BELLEVUE, Wash.—February 10, 2026—A new peer-reviewed study led by Truveta Research and collaborators finds that the US Food and Drug Administration’s (FDA) March 2024 expansion of semaglutide’s cardiovascular indication was followed by a rapid but short-lived...
Truveta deepens regulatory science leadership with appointment of John D. Seeger, PharmD, DrPH, FISPE as Senior Vice President of Evidence Services
Globally recognized pharmacoepidemiologist brings decades of experience advancing real-world evidence for regulatory decision-making. BELLEVUE, Wash.—February 9, 2026—Truveta today announced the appointment of John D. Seeger, PharmD, DrPH, FISPE, a global leader in...
Truveta Research study published in Contraception advances understanding of women’s health and clinical guideline adoption
BELLEVUE, Wash.—February 2, 2026—Truveta today announced the publication of a new Truveta Research study in Contraception, a leading peer-reviewed journal in reproductive health. The study leverages real-world data to examine trends in pain management during...
Truveta launches real-time clinical trials solution to accelerate study design, enrollment, and evidence generation
Bellevue, WA — January 27, 2026 — Truveta today announced the launch of its new clinical trials solution that enables trial sponsors to design, optimize, and execute clinical studies using the most complete, daily refreshed real-world data in the United States. Built...
